No time for complacency on COVID-19 in Europe.

Authors:
Flahault A; Calmy A; Costagliola D; Drapkina O; Eckerle I and 5 more

Journal:
Lancet

Publication Year: 2023

DOI:
10.1016/S0140-6736(23)01012-7

PMCID:
PMC10202416

PMID:
37230103

Journal Information

Full Title: Lancet

Abbreviation: Lancet

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"AF is Chair of and AC, DC, OD, IE, HJL, HL-Q, CN, and MK are members of the High-Level Expert Group for COVID-19 that has advised Hans Kluge since 2021. HK is the Regional Director of the WHO Regional Office for Europe. AC report grants from ViiV Healthcare, Gilead Sciences, and MSD and is the principal investigator of the OPTICOV trial. DC report institutional grant from Janssen and honoraria for lectures from Gilead and Pfizer. HJL reports grants from GSK, Merck, and a MacArthur Award for the Vaccine Confidence Project and honoraria for lectures from UNC and NYU. HL-Q was a member of the Secretariat of the Independent Panel for Pandemic Preparedness and Response. CN reports grants from the Engineering and Physical Sciences Research Council, the UK Department of Health and Social Care, the Natural Environment Research Council, NHS Scotland, and the UK Government for various projects on transmission of COVID-19; is a member of the UK Government SAGE Committee, Co-Chair of SAGE Environment and Modelling group, is a member of multiple UK and Scottish Government and NHS working groups on COVID-19, is a member of WHO ECAP, and a member of the Royal Academy of Engineering and Academy of Medical Sciences working groups on COVID-19 mitigation. MK is an independent Board member of ExevirBio, a biotechnology company designing therapeutic monoclonal antibodies against SARS Cov2. We declare no other competing interests."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025